Zoledronic Acid

CHEMBL4303669 Phase 4 已批准 Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

272.1 g/mol

LogP

-4.3

Phase

4

This bisphosphonate medication is given as an annual or more frequent intravenous infusion to treat osteoporosis and prevent bone fractures, and is also used to treat elevated calcium caused by cancer, bone complications from multiple myeloma, and bone metastases from solid tumors. It works by attaching to bone surfaces and blocking the cells (osteoclasts) that break down bone, preserving bone density. Flu-like symptoms are common after the first infusion, and a rare but serious complication is osteonecrosis of the jaw, particularly in cancer patients.

分子量

272.0900 g/mol

LogP

-4.30

TPSA

153.00 Å²

Lipinski 五规则

符合

治疗领域

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Age-Related Macular Degeneration Pain Management Non-Small Cell Lung Cancer Osteoporosis Parkinson's Disease Multiple Sclerosis Oncology Stroke Lymphoma Breast Cancer Chronic Pain Prostate Cancer Colorectal Cancer Leukemia

Pharmacokinetics (PK)

Pharmacodynamics (PD)

二维结构

SVG PNG

Cite this structure

Embed this structure

SMILES

O.O=P(O)(O)C(O)(Cn1ccnc1)P(=O)(O)O

InChI

InChI=1S/C5H10N2O7P2.H2O/c8-5(15(9,10)11,16(12,13)14)3-7-2-1-6-4-7;/h1-2,4,8H,3H2,(H2,9,10,11)(H2,12,13,14);1H2

Molecular Formula

C5H10N2O7P2

HBD / HBA

5 / 8

可旋转键数

4

重原子数

16

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

常见问题

This bisphosphonate medication is given as an annual or more frequent intravenous infusion to treat osteoporosis and prevent bone fractures, and is also used to treat elevated calcium caused by cancer, bone complications from multiple myeloma, and bone metastases from solid tumors. It works by attaching to bone surfaces and blocking the cells (osteoclasts) that break down bone, preserving bone density. Flu-like symptoms are common after the first infusion, and a rare but serious complication is osteonecrosis of the jaw, …

Yes, Zoledronic Acid is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4303669. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 68740. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

正在寻找患者友好型信息？

Zoledronic Acid 在 PillFYI 上

结构

快速数据

分子式: C5H10N2O7P2
同义词: 1

外部链接

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

医疗免责声明

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.